drugset / Trial / NCT04694365
Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Liver Function
Non-randomizedParallel-groupOpen-labelBasic science
Summary
This study is designed to evaluate the safety and pharmacokinetics of Fluzoparib in subjects with impaired liver function in comparison with healthy subjects ,to develop dose recommendations for patients with hepatic impairment.
Timeline
- Start
- 2021-03-01
- Primary completion
- 2024-06-19
- Completion
- 2024-06-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluzoparib | Small molecule | 50 mg | Oral |
Indications
No indication recorded.